# Janssen Scientific Affairs, LLC clinical trials: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with Janssen Scientific Affairs, LLC as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen Scientific Affairs, LLC: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-scientific-affairs-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2023 | NCT06052319 | A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD)... | Janssen Scientific Affairs, LLC | Observational | Completed | Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD) | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06052319) |
| April 26, 2022 | NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Janssen Scientific Affairs, LLC | Phase 2 | Completed | Multiple Myeloma | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05347485) |
| April 26, 2022 | NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | Janssen Scientific Affairs, LLC | Not applicable | Available | Multiple Myeloma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05346835) |
| June 23, 2020 | NCT04442737 | A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in... | Janssen Scientific Affairs, LLC | Phase 4 | Completed | HIV-1 | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04442737) |
| May 1, 2020 | NCT04372108 | A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis | Janssen Scientific Affairs, LLC | Observational | Recruiting | Crohn Disease, Colitis, Ulcerative | 1,536 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04372108) |
| February 19, 2020 | NCT04276441 | A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World | Janssen Scientific Affairs, LLC | Observational | Completed | Atrial Fibrillation | 34,244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04276441) |
| January 31, 2019 | NCT03825484 | Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who... | Janssen Scientific Affairs, LLC | Not applicable | Approved for marketing | Advanced Cancers and FGFR Genetic Alterations | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03825484) |
| June 27, 2018 | NCT03571685 | Sustainable Early Episode Clinic Study (SEEC) | Janssen Scientific Affairs, LLC | Not applicable | Completed | Schizophrenia, Schizoaffective Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03571685) |
| March 13, 2018 | NCT03464136 | Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year | Janssen Scientific Affairs, LLC | Phase 3 | Completed | Crohn Disease | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03464136) |
| December 26, 2017 | NCT03382613 | A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation | Janssen Scientific Affairs, LLC | Observational | Terminated | Atrial Fibrillation | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03382613) |
| July 24, 2017 | NCT03227861 | A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed... | Janssen Scientific Affairs, LLC | Phase 3 | Completed | HIV-1 | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03227861) |
| June 8, 2017 | NCT03180853 | Multiple Myeloma Patient Registry | Janssen Scientific Affairs, LLC | Observational | Terminated | Multiple Myeloma | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03180853) |
| March 21, 2017 | NCT03085108 | A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment | Janssen Scientific Affairs, LLC | Observational | Completed | Suicidality | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03085108) |
| December 19, 2016 | NCT02996435 | Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation | Janssen Scientific Affairs, LLC | Phase 4 | Completed | Atrial Fibrillation | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02996435) |
| December 7, 2016 | NCT02984852 | Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide... | Janssen Scientific Affairs, LLC | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02984852) |
| November 1, 2016 | NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | Janssen Scientific Affairs, LLC | Phase 2 | Completed | Multiple Myeloma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02951819) |
| April 5, 2016 | NCT02728934 | Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis | Janssen Scientific Affairs, LLC | Observational | Completed | Arthritis, Rheumatoid | 1,279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02728934) |
| January 26, 2016 | NCT02663193 | Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | Janssen Scientific Affairs, LLC | Observational | Completed | Prostate Cancer | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02663193) |
| November 9, 2015 | NCT02600741 | Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) | Janssen Scientific Affairs, LLC | Observational | Completed | Schizophrenia | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02600741) |
| October 22, 2015 | NCT02584660 | A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department | Janssen Scientific Affairs, LLC | Phase 4 | Completed | Pulmonary Embolism | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02584660) |
| October 2, 2015 | NCT02566889 | An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease | Janssen Scientific Affairs, LLC | Phase 4 | Terminated | Inflammatory Bowel Diseases | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02566889) |
| September 28, 2015 | NCT02561923 | A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in... | Janssen Scientific Affairs, LLC | Phase 1 | Completed | Healthy | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02561923) |
| May 1, 2015 | NCT02431702 | A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral... | Janssen Scientific Affairs, LLC | Phase 3 | Completed | Schizophrenia, Psychotic Disorders | 337 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431702) |
| December 4, 2014 | NCT02307864 | Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants | Janssen Scientific Affairs, LLC | Phase 1 | Completed | Healthy | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02307864) |
| June 17, 2014 | NCT02165189 | An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C... | Janssen Scientific Affairs, LLC | Phase 2 | Completed | Hepatitits C | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02165189) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 8 |
| Not applicable | 3 |
| Observational | 14 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Terminated | 3 |
| Available | 1 |
| Active not recruiting | 1 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Atrial Fibrillation | 7 |
| Multiple Myeloma | 5 |
| Schizophrenia | 5 |
| Arrhythmias, Cardiac | 4 |
| Psychotic Disorders | 3 |
| Crohn Disease | 3 |
| Pain | 2 |
| Colitis, Ulcerative | 2 |
| Inflammatory Bowel Diseases | 2 |
| Hepatitis C | 1 |
| Long QT Syndrome | 1 |
| Psoriasis | 1 |
| Arthritis, Psoriatic | 1 |
| Skin Diseases | 1 |
| HIV Infections | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Suicidal Ideation | 1 |
| Arthritis, Rheumatoid | 1 |
| Prostatic Neoplasms | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Hypertension | 1 |
| Pediatric ulcerative colitis | 1 |
| Pediatric Crohn's disease | 1 |
| Bipolar Disorder | 1 |
| Coronary Artery Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Deck builders in the United States](https://specstream.ai/data/businesses/deck-builders/united-states)
- [B2B advertising and marketing companies in the United States](https://specstream.ai/data/businesses/b2b-advertising-and-marketing-companies/united-states)
- [Sri Lankan restaurants in the United States](https://specstream.ai/data/businesses/sri-lankan-restaurants/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Home cleaning companies in the United States](https://specstream.ai/data/businesses/home-cleaning-companies/united-states)
